IMMNOV — Immunovia AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK108.57m
- SEK31.97m
- SEK0.69m
Annual income statement for Immunovia AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.844 | 1.15 | 1.57 | 0.931 | 0.685 |
| Cost of Revenue | |||||
| Gross Profit | -66.8 | -80.8 | -73.8 | -64.5 | -43 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 167 | 192 | 298 | 110 | 81.1 |
| Operating Profit | -167 | -191 | -296 | -109 | -80.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -156 | -168 | -309 | -76.5 | -146 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -156 | -168 | -309 | -76.5 | -146 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -156 | -168 | -309 | -76.5 | -146 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -156 | -168 | -309 | -76.5 | -146 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.47 | -2.66 | -2.25 | -0.72 | -0.424 |
| Dividends per Share |